|
|
LDL and cardiovascular disease: Latest insights
|
|
|
|
New Approaches to LDL Reduction and HDL Increase
|
|
|
|
Ezetimibe strongly increases TICE
|
|
|
|
Prospective Clinical Events Trials Examining the Effects of Statins in ESRD Patients
|
|
|
|
Relationship Between GFR and CVD Outcomes
|
|
|
|
4D Study
|
|
|
|
4D Study
|
|
|
|
AURORA Study
|
|
|
|
AURORA Study Design
|
|
|
|
AURORA Study: Cumulative Incidence of Primary Endpoint
|
|
|
|
The results of the Study of Heart and Renal Protection (SHARP)
|
|
|
|
SHARP: Rationale
|
|
|
|
SHARP: Eligibility
|
|
|
|
SHARP: Assessment of LDL-lowering
|
|
|
|
SHARP: Baseline characteristics
|
|
|
|
SHARP: Compliance and LDL-C reduction at study midpoint
|
|
|
|
SHARP: Baseline paper and Data Analysis Plan
|
|
|
|
SHARP: Main outcomes
|
|
|
|
SHARP: Major Atherosclerotic Events
|
|
|
|
CTT: Effects on Major Atherosclerotic Events
|
|
|
|
CTT: Effects on Major Atherosclerotic Events
|
|
|
|
SHARP: Major Vascular Events
|
|
|
|
SHARP: Effects in subgroups
|
|
|
|
SHARP: Major Atherosclerotic Events by renal status at randomization
|
|
|
|
SHARP: Cause-specific mortality
|
|
|
|
SHARP: Renal outcomes
|
|
|
|
SHARP: Cancer incidence
|
|
|
|
SHARP: Safety
|
|
|
|
SHARP: Conclusions
|
|
|
|
The Inhibition of Cholesterol Ester Transfer Protein
|
|
|
|
CETP Levels and CAD risk: The EPIC – Norfolk study
|
|
|
|
Scientific Case for Developing the CETP inhibitor Anacetrapib
|
|
|
|
Anacetrapib Dose Ranging Study
|
|
|
|
Effect of HDL from Anacetrapib-treated Patients on Cholesterol Efflux from Human Macrophages
|
|
|
|
Effect of Torcetrapib and Anacetrapib on Blood Pressure in Rhesus Monkeys
|
|
|
|
The Effect of Torcetrapib and Anacetrapib on Aldosterone Secretion from Primary Rat Adrenocortical Cells
|
|
|
|
Effects on LDL-C and HDL-C
|
|
|
|
Conclusion
|
|
|
|
Future
|
|
|
|
Nicotinic Acid Treatment of Dyslipidemia and Atherosclerosis
|
|
|
|
Niacin Raises HDL-C and Decreases LDL-C, TG, and Lp(a) in a Dose-Dependent Manner
|
|
|
|
Effectiveness of 2 g vs 1 g of ER Niacin
|
|
|
|
Most Patients on ER Niacin Therapy Do Not Reach a 2-g Dose
|
|
|
|
Niacin Flushing Pathway: Two Separate Steps and Sites of Action
|
|
|
|
Lipid/Flushing Study: Lower Incidence of Moderate or Greater Flushing vs ER Niacin
|
|
|
|
Factorial Study: Lipid Efficacy
|
|
|
|
HPS2-THRIVE
|
|
|
|
Conclusion
|
|
08_J._Kastelein (PPTX 1,8MB)
Deel deze pagina met collega's en vrienden: